We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+23.65%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.28B
AUM Growth
+$464M
Cap. Flow
-$292M
Cap. Flow %
-5.53%
Top 10 Hldgs %
49.47%
Holding
185
New
37
Increased
47
Reduced
83
Closed
9

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$120M
2
FOLD
Amicus Therapeutics
FOLD
+$105M
3
NUVL
Nuvalent
NUVL
+$102M
4
KRYS icon
Krystal Biotech
KRYS
+$86.1M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$75.6M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$149M
2
INCY icon
Incyte
INCY
+$139M
3
AKRO
Akero Therapeutics
AKRO
+$113M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$109M
5
ARGX icon
argenx
ARGX
+$72.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.71%
2 Technology 0.1%
3 Consumer Discretionary 0.05%
4 Financials 0.03%
5 Communication Services 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$39.6B
$399M 7.56%
5,005,719
-568,119
-10% -$37.3M
ARGX icon
2
argenx
ARGX
$53.8B
$388M 7.36%
461,854
-84,474
-15% -$72.3M
IONS icon
3
Ionis Pharmaceuticals
IONS
$8.99B
$380M 7.2%
4,802,199
-1,442,252
-23% -$109M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$123B
$309M 5.85%
681,120
+175,315
+35% +$75.6M
NBIX icon
5
Neurocrine Biosciences
NBIX
$17.2B
$242M 4.58%
1,703,304
-59,801
-3% -$8.66M
RNAM
6
DELISTED
Avidity Biosciences
RNAM
$190M 3.6%
2,630,969
+478,107
+22% +$30.9M
ISRG icon
7
Intuitive Surgical
ISRG
$122B
$182M 3.46%
322,028
-26,598
-8% -$14.2M
SRRK icon
8
Scholar Rock
SRRK
$6.33B
$179M 3.39%
4,056,592
+812,055
+25% +$30.5M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$35.7B
$177M 3.36%
445,903
-621
-0.1% -$275K
ABT icon
10
Abbott
ABT
$175B
$165M 3.13%
1,316,915
-161,648
-11% -$20.6M
FOLD
11
DELISTED
Amicus Therapeutics
FOLD
$153M 2.9%
+10,735,195
New +$105M
BSX icon
12
Boston Scientific
BSX
$65.4B
$149M 2.82%
1,559,606
-100,243
-6% -$9.83M
VRDN icon
13
Viridian Therapeutics
VRDN
$1.99B
$136M 2.57%
+4,358,527
New +$120M
SYK icon
14
Stryker
SYK
$123B
$127M 2.4%
360,577
-90,519
-20% -$33M
NUVL
15
DELISTED
Nuvalent
NUVL
$104M 1.98%
+1,037,468
New +$102M
KRYS icon
16
Krystal Biotech
KRYS
$10.5B
$101M 1.92%
410,323
+409,011
+31,175% +$86.1M
CLDX icon
17
Celldex Therapeutics
CLDX
$2.77B
$98.3M 1.86%
3,617,669
+60,000
+2% +$1.58M
IMCR icon
18
Immunocore
IMCR
$1.78B
$97.1M 1.84%
2,796,803
– –
EW icon
19
Edwards Lifesciences
EW
$49.4B
$88.9M 1.69%
1,043,096
+146,463
+16% +$12M
VERA icon
20
Vera Therapeutics
VERA
$2.76B
$86M 1.63%
+1,698,152
New +$60.3M
MDT icon
21
Medtronic
MDT
$106B
$73.6M 1.4%
766,592
+6,731
+0.9% +$654K
RLAY icon
22
Relay Therapeutics
RLAY
$4.34B
$70.6M 1.34%
8,345,364
-246
-0% -$1.75K
IDXX icon
23
Idexx Laboratories
IDXX
$44.8B
$64M 1.21%
94,539
+17,952
+23% +$12.2M
UNH icon
24
UnitedHealth
UNH
$387B
$57.8M 1.1%
175,169
+5,112
+3% +$1.73M
DXCM icon
25
DexCom
DXCM
$29.6B
$56.2M 1.07%
847,405
+61,287
+8% +$3.96M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2025 Portfolio in Review

As of Q4 2025, Bellevue Group held 185 positions worth $5.28B, up 9.6% from $4.81B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Bellevue Group withdrew a net $292M in Q4 2025, closing 9 positions and reducing 83 holdings. Its most notable exit was Agios Pharmaceuticals, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Bellevue Group opened a new position in Viridian Therapeutics worth $136M.

  • Bellevue Group's largest Q4 2025 buy was Viridian Therapeutics: 4,358,527 shares worth $136M.
  • Bellevue Group added most to Krystal Biotech in Q4 2025, an estimated $86.1M increase.
  • Bellevue Group's biggest Q4 2025 reduction was Incyte, cutting an estimated $139M.
  • Bellevue Group fully exited Agios Pharmaceuticals in Q4 2025, selling an estimated $149M.
  • Bellevue Group's ten largest holdings make up 49% of its $5.28B portfolio in Q4 2025.
  • Bellevue Group opened 37 new positions and closed 9 in Q4 2025.
  • Bellevue Group's portfolio value rose 9.6% quarter-over-quarter to $5.28B.

Based on Bellevue Group's 13F filing for Q4 2025, filed 17 Feb 2026.